A detailed history of Stratos Wealth Partners, Ltd. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Stratos Wealth Partners, Ltd. holds 222,909 shares of BMY stock, worth $11.9 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
222,909
Previous 204,090 9.22%
Holding current value
$11.9 Million
Previous $8.48 Million 36.11%
% of portfolio
0.17%
Previous 0.14%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

BUY
$39.66 - $51.75 $746,361 - $973,883
18,819 Added 9.22%
222,909 $11.5 Million
Q2 2024

Jul 24, 2024

SELL
$40.25 - $52.99 $69,994 - $92,149
-1,739 Reduced 0.84%
204,090 $8.48 Million
Q1 2024

Apr 16, 2024

BUY
$47.98 - $54.4 $287,784 - $326,291
5,998 Added 3.0%
205,829 $11.2 Million
Q4 2023

Jan 24, 2024

SELL
$48.48 - $57.85 $299,897 - $357,860
-6,186 Reduced 3.0%
199,831 $10.3 Million
Q3 2023

Oct 24, 2023

BUY
$57.89 - $64.73 $226,697 - $253,482
3,916 Added 1.94%
206,017 $12 Million
Q2 2023

Jul 18, 2023

BUY
$63.71 - $70.74 $30,899 - $34,308
485 Added 0.24%
202,101 $12.9 Million
Q1 2023

Apr 27, 2023

SELL
$65.71 - $74.53 $515,232 - $584,389
-7,841 Reduced 3.74%
201,616 $14 Million
Q4 2022

Jan 19, 2023

BUY
$68.48 - $81.09 $89,503 - $105,984
1,307 Added 0.63%
209,457 $0
Q3 2022

Oct 24, 2022

SELL
$0.13 - $76.84 $145 - $85,983
-1,119 Reduced 0.53%
208,150 $14.8 Million
Q2 2022

Jul 22, 2022

SELL
$72.62 - $79.98 $77,630 - $85,498
-1,069 Reduced 0.51%
209,269 $16.1 Million
Q1 2022

Apr 26, 2022

SELL
$61.48 - $73.72 $201,900 - $242,096
-3,284 Reduced 1.54%
210,338 $15.4 Million
Q4 2021

Jan 14, 2022

SELL
$53.63 - $62.52 $405,389 - $472,588
-7,559 Reduced 3.42%
213,622 $13.3 Million
Q3 2021

Oct 19, 2021

SELL
$59.17 - $69.31 $11,952 - $14,000
-202 Reduced 0.09%
221,181 $13.1 Million
Q2 2021

Jul 19, 2021

BUY
$61.91 - $67.42 $20,987 - $22,855
339 Added 0.15%
221,383 $14.8 Million
Q1 2021

Apr 27, 2021

SELL
$59.34 - $66.74 $649,357 - $730,335
-10,943 Reduced 4.72%
221,044 $14 Million
Q4 2020

Jan 29, 2021

SELL
$57.74 - $65.43 $590,045 - $668,629
-10,219 Reduced 4.22%
231,987 $14.4 Million
Q3 2020

Oct 29, 2020

BUY
$57.43 - $63.64 $307,767 - $341,046
5,359 Added 2.26%
242,206 $14.6 Million
Q2 2020

Jul 28, 2020

SELL
$54.82 - $64.09 $1.35 Million - $1.57 Million
-24,565 Reduced 9.4%
236,847 $13.9 Million
Q1 2020

May 04, 2020

SELL
$46.4 - $67.43 $740,729 - $1.08 Million
-15,964 Reduced 5.76%
261,412 $14.6 Million
Q4 2019

Jan 29, 2020

BUY
$49.21 - $64.19 $844,591 - $1.1 Million
17,163 Added 6.6%
277,376 $17.8 Million
Q3 2019

Nov 12, 2019

BUY
$42.77 - $50.71 $11.1 Million - $13.2 Million
259,809 Added 64309.16%
260,213 $13.2 Million
Q3 2019

Nov 12, 2019

SELL
$42.77 - $50.71 $11.1 Million - $13.1 Million
-259,210 Reduced 99.84%
404 $14.1 Million
Q2 2019

Aug 06, 2019

SELL
$44.62 - $49.34 $787,810 - $871,147
-17,656 Reduced 6.37%
259,614 $11.8 Million
Q1 2019

May 07, 2019

SELL
$45.12 - $53.8 $249,784 - $297,836
-5,536 Reduced 1.96%
277,270 $13.2 Million
Q4 2018

Feb 08, 2019

SELL
$48.76 - $63.23 $385,594 - $500,022
-7,908 Reduced 2.72%
282,806 $14.7 Million
Q3 2018

Nov 02, 2018

SELL
$55.19 - $62.25 $123,791 - $139,626
-2,243 Reduced 0.77%
290,714 $18 Million
Q2 2018

Aug 13, 2018

SELL
$50.53 - $62.98 $328,697 - $409,684
-6,505 Reduced 2.17%
292,957 $16.2 Million
Q1 2018

May 10, 2018

SELL
$59.92 - $68.98 $511,836 - $589,227
-8,542 Reduced 2.77%
299,462 $18.9 Million
Q4 2017

Feb 09, 2018

SELL
$59.94 - $65.35 $395,364 - $431,048
-6,596 Reduced 2.1%
308,004 $18.9 Million
Q3 2017

Nov 07, 2017

BUY
$55.23 - $63.74 $17.4 Million - $20.1 Million
314,600
314,600 $20.1 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Stratos Wealth Partners, Ltd. Portfolio

Follow Stratos Wealth Partners, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stratos Wealth Partners, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Stratos Wealth Partners, Ltd. with notifications on news.